| 1 |
-
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
-
12/26/2025 10:27:34 AM | Browse: 18 | Download: 50
|
| 2 |
-
Application of stem cells in the precise diagnosis and treatment of liver diseases
-
12/10/2025 7:48:06 AM | Browse: 9 | Download: 45
|
| 3 |
-
OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening
-
9/25/2025 9:22:02 AM | Browse: 104 | Download: 116
|
| 4 |
-
Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients
-
6/23/2025 7:18:41 AM | Browse: 84 | Download: 533
|
| 5 |
-
Gut feeling gone wrong: Tangled relationship between disorders of gut-brain interaction and liver disease
-
5/27/2025 7:04:47 AM | Browse: 40 | Download: 298
|
| 6 |
-
Mixed lineage kinase domain-like protein in liver diseases: Cell-type-specific functions and dual roles
-
4/11/2025 2:19:31 AM | Browse: 65 | Download: 388
|
| 7 |
-
Targeting mixed lineage kinase domain-like protein's non-necroptosis role: A new horizon in anti-inflammatory therapy for alcoholic liver disease
-
4/2/2025 10:54:11 AM | Browse: 62 | Download: 382
|
| 8 |
-
Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis
-
3/26/2025 4:06:52 AM | Browse: 98 | Download: 333
|
| 9 |
-
Current impact in the treatment of advanced hepatocellular carcinoma: The challenge remains
-
2/14/2025 10:33:25 AM | Browse: 118 | Download: 376
|
| 10 |
-
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
-
12/30/2024 6:47:30 AM | Browse: 55 | Download: 382
|
| 11 |
-
Diagnostic value of tissue plasminogen activator-inhibitor complex in sepsis-induced liver injury: A single-center retrospective case-control study
-
11/6/2024 9:50:59 AM | Browse: 148 | Download: 744
|
| 12 |
-
Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis
-
10/31/2024 7:40:50 AM | Browse: 110 | Download: 620
|
| 13 |
-
Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
-
10/16/2024 6:29:25 AM | Browse: 115 | Download: 399
|
| 14 |
-
Interleukin-mediated therapies in liver diseases and comorbidity effects
-
7/26/2024 10:33:29 AM | Browse: 179 | Download: 551
|
| 15 |
-
Immunological crossroads: The intriguing dance between hepatitis C and autoimmune hepatitis
-
6/20/2024 3:42:22 AM | Browse: 160 | Download: 483
|
| 16 |
-
Revolutionizing disease diagnosis and management: Open-access magnetic resonance imaging datasets a challenge for artificial intelligence driven liver iron quantification
-
6/4/2024 3:55:01 PM | Browse: 128 | Download: 617
|
| 17 |
-
Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections
-
2/27/2024 11:58:45 AM | Browse: 221 | Download: 903
|
| 18 |
-
Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis
-
10/24/2023 8:39:24 AM | Browse: 295 | Download: 940
|
| 19 |
-
Advances in application of novel magnetic resonance imaging technologies in liver disease diagnosis
-
7/26/2023 11:55:37 AM | Browse: 295 | Download: 855
|
| 20 |
-
COVID-19-induced liver injury in infants, children, and adolescents
-
6/8/2023 9:24:51 AM | Browse: 383 | Download: 997
|
| 21 |
-
Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features
-
2/6/2023 12:22:17 PM | Browse: 463 | Download: 976
|
| 22 |
-
Iron as a therapeutic target in chronic liver disease
-
1/20/2023 1:48:21 PM | Browse: 325 | Download: 1017
|
| 23 |
-
Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases
-
6/28/2022 9:38:07 AM | Browse: 711 | Download: 1706
|
| 24 |
-
COVID-19 and liver diseases, what we know so far
-
4/30/2022 5:08:22 AM | Browse: 549 | Download: 1198
|
| 25 |
-
COVID-19, liver dysfunction and pathophysiology: A conceptual discussion
-
2/9/2022 7:25:27 AM | Browse: 625 | Download: 1490
|
| 26 |
-
Emerging artificial intelligence applications in liver magnetic resonance imaging
-
10/27/2021 7:14:11 AM | Browse: 609 | Download: 1437
|
| 27 |
-
Liver and COVID-19: From care of patients with liver diseases to liver injury
-
10/22/2021 1:53:28 PM | Browse: 607 | Download: 1382
|
| 28 |
-
Factors predicting futility of liver transplant in elderly recipients: A single-center experience
-
10/14/2021 9:37:43 AM | Browse: 802 | Download: 1728
|
| 29 |
-
Malnutrition and liver disease in a developing country
-
8/10/2021 6:48:42 AM | Browse: 708 | Download: 1652
|
| 30 |
-
Liver dysfunction and SARS-CoV-2 infection
-
7/12/2021 12:42:13 AM | Browse: 775 | Download: 1535
|
| 31 |
-
Viscoelastic tests in liver disease: where do we stand now?
-
6/18/2021 5:06:16 AM | Browse: 671 | Download: 1538
|
| 32 |
-
Role of bile acids in liver diseases mediated by gut microbiome
-
6/8/2021 10:51:03 AM | Browse: 677 | Download: 1870
|
| 33 |
-
Bile acid indices as biomarkers for liver diseases I: Diagnostic markers
-
4/16/2021 10:13:42 AM | Browse: 692 | Download: 1776
|
| 34 |
-
COVID-19 and co-morbidities of hepatic diseases in a global perspective
-
3/30/2021 7:03:44 AM | Browse: 690 | Download: 1601
|
| 35 |
-
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
-
12/21/2020 12:21:52 PM | Browse: 881 | Download: 1527
|
| 36 |
-
Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
-
11/24/2020 12:41:21 PM | Browse: 787 | Download: 2250
|
| 37 |
-
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
-
9/21/2020 4:02:08 PM | Browse: 833 | Download: 2038
|
| 38 |
-
Progress of intravoxel incoherent motion diffusion-weighted imaging in liver diseases
-
8/6/2020 9:52:05 AM | Browse: 882 | Download: 1721
|
| 39 |
-
Role of γδT cells in liver diseases and its relationship with intestinal microbiota
-
5/28/2020 1:08:01 PM | Browse: 1125 | Download: 2162
|
| 40 |
-
Role of spleen tyrosine kinase in liver diseases
-
3/14/2020 3:03:29 PM | Browse: 1094 | Download: 1759
|
| 41 |
-
Study on serum amyloid A levels in patients with liver diseases
-
11/21/2019 8:40:16 AM | Browse: 1253 | Download: 2440
|
| 42 |
-
Organoids of liver diseases: From bench to bedside
-
4/25/2019 3:13:57 AM | Browse: 1043 | Download: 2010
|
| 43 |
-
Extreme hyperbilirubinemia: An indicator of morbidity and mortality in sickle cell disease
-
3/27/2019 10:37:20 AM | Browse: 1218 | Download: 2035
|
| 44 |
-
Dental pulp cell bank as a possible future source of individual hepatocytes
-
10/27/2018 4:40:10 AM | Browse: 1297 | Download: 1779
|
| 45 |
-
Alkaline sphingomyelinase (NPP7) in hepatobiliary diseases: A field that needs to be closely studied
-
3/4/2018 12:36:47 PM | Browse: 1168 | Download: 1499
|
| 46 |
-
Genetic variants of interferon regulatory factor 5 associated with chronic hepatitis B infection
-
1/14/2018 5:07:58 AM | Browse: 1363 | Download: 1762
|
| 47 |
-
Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis
-
7/20/2017 10:12:50 AM | Browse: 1649 | Download: 2216
|
| 48 |
-
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
-
6/14/2017 9:25:57 AM | Browse: 1228 | Download: 2150
|
| 49 |
-
MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis b- and c-related-hepatocellular-carcinoma
-
4/12/2016 1:04:00 PM | Browse: 1683 | Download: 3228
|
| 50 |
-
Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications
-
12/31/2015 1:27:00 PM | Browse: 1343 | Download: 1792
|
